Koppel to Leave Biogen, Return to Bain Capital

Xconomy Boston — 

After a roughly two-year stint running Biogen’s (NASDAQQ: BIIB) dealmaking efforts, Adam Koppel is returning to his previous employer, Bain Capital. Koppel, who was named Biogen’s chief strategy officer in 2014, will step down on June 2 and head back to Bain as a managing director, where he’ll make private investments in biotech and life sciences companies. His role at Biogen will be split between CEO George Scangos, newly hired research chief Michael Ehlers, and chief financial officer Paul Clancy.